Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 1/20 | 0.50 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | PYGB | P11216 | 8/20 | 0.35 |
| ▸ | PYGL | P06737 | 3/20 | 0.35 |
| ▸ | PYGM | P11217 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22367602 | 1.00 | CDK1 (0.50) | CDK1CCNB1CA2CA9PYGB | |
| SCHEMBL18179078 | 0.84 | CDK1 (0.49) | CDK1CCNB1CA2CA9PYGB | |
| SCHEMBL20552346 | 0.84 | CDK1 (0.49) | CDK1CCNB1CA2CA9PYGB | |
| SCHEMBL5148638 | 0.84 | CDK1 (0.49) | CDK1CCNB1CA2CA9PYGB | |
| SCHEMBL4280532 | 0.84 | CDK1 (0.49) | CDK1CCNB1CA2CA9PYGB | |
| SCHEMBL28266643 | 0.84 | CDK1 (0.49) | CDK1CCNB1CA2CA9PYGB | |
| SCHEMBL3788926 | 0.84 | CDK1 (0.48) | CDK1CCNB1CA2CA9PYGB | |
| SCHEMBL10910296 | 0.84 | CDK1 (0.48) | CDK1CCNB1CA2CA9PYGB | |
| SCHEMBL3788922 | 0.84 | CDK1 (0.48) | CDK1CCNB1CA2CA9PYGB | |
| SCHEMBL13264607 | 0.84 | CDK1 (0.48) | CDK1CCNB1CA2CA9PYGB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200345858-A1 | COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF ERGOT ALKALOID TOXICITY | LINDA LIGHT | 2020-11-05 | — | — | US | disclosed |
| EP-3700523-A1 | COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF ERGOT ALKALOID TOXICITY | Light, Linda (US) | 2020-09-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200345858-A1 | COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF ERGOT ALKALOID TOXICITY | FH, CRH, HYPK | CDK1 2848/4885CCNB1 4033/4885CA2 3111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.